chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient arrived to clinic for 1st dose of pediatric pfizer vaccine. Vaccination was completed successfully with no immediate complaints from the patient. Approximately 10 minutes post-vaccination patient complained of nausea. Patient was brought to a restroom by parent and patient and parent reported that he vomited. Patient appeared pale/gray complexion RN's assessment. Parent reported that patient had not had anything to eat or drink yet this morning. Patient was asked to sit in a chair and drink small amounts of juice and was given pretzels. Patient's coloring improved with food and drink. Patient was observed for a total of 30 minutes with no other complaints except nausea which improved during observation. Parent reported that patient can get carsick, staff provided parent with emesis bag in case of nausea presenting again. Parent reported they would be getting food after leaving clinic site.
81 year old female admitted to healthcare facility for  deep vein thrombosis and pulmonary emboli. Hospitalized x 14 days; treated by healthcare provider. Patient sought care after Chiropractor noted her right leg was swollen and he told her she should investigate this problem. Patient was then seen by healthcare provider who sent her for diagnostic testing - Doppler of lower extremities, and CT scan of Lungs. Pt was referred to a pulmonary specialist; Pt was hospitalized and treated with Heparin and Coumadin, and Oxygen.
Varicella-Mom reports varicella like rash and fever. Diagnosed in office with Post Immunization Reaction- crusted lesions from Varicella vaccination. Suspected Fifths Disease, viral type syndrome. History of slapped cheeks and now blotchy erythema.  Hep A- Mom self reports fever, rash. Patient was not seen in office.
This spontaneous report as received from an office manager refers to an unspecified number of patients of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. It was reported that between 30-JUN-2015 and 18-AUG-2015, the patients were vaccinated with the improperly stored doses of GARDASIL (lot # K010215 with expiration date 06-MAY-2017; dose and route of administration were not reported). No adverse effects were reported. Additional information has been requested.
Information has been received from a physician concerning a 1 year old female who was vaccinated with a dose of measles virus vaccine live (+) mumps virus vaccine (+) rubella virus vaccine. Subsequently the patient developed a macular rash. It was unknown if medical attention was sought. There was no product quality complaint involved. Additional information has been requested.
My upper arm is red at the site of the injection.  Redness goes from just below shoulder to just above elbow.
He woke up the next morning from shoulder to wrist was red and hot to touch. I gave me Tylenol. I called the doctor office spoke with a triage nurse. The nurse recommended Tylenol and Motrin and Benadryl and cold compresses and if he were to get worse to bring him in. That evening it started improving.
pt w/asthma devel severe SOB, asthma attack w/in 10 mins of vax; attack was immed w/no inc SOB or in SOB to warn of attack;
Headache, Soreness and bump at injection site, congestion, some chills, and tiredness.
Information has been received from a mother concerning her 6 month old daughter with an unremarkable medical history and no allergies who on 28 Sep 2006 was vaccinated PO with the first 2.0 mL dose of Rotateq. Concomitant vaccinations administered on that same day included a dose of poliovirus vaccine, a dose of diphtheria toxoid (+) pertussis acellular vaccine (unspecified) (+) tetanus toxoid and a dose of hepatitis B. The mother reported that on approximately 30 Sep 2006, her daughter became severely constipated. Unspecified medical attention was sought. No laboratory/diagnostic tests were performed. The patient's mother noted that her daughter received all three doses of Rotateq per the appropriate schedule with the third dose having been administered on 29 Jan 2007. At the time of this report, the patient remained severely constipated. Additional information has been requested.
Chills; Headache; Chills; Headache; This spontaneous case was reported by a consumer and describes the occurrence of the first episode of CHILLS (Chills), the first episode of HEADACHE (Headache), the second episode of CHILLS (Chills) and the second episode of HEADACHE (Headache) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced the first episode of CHILLS (Chills) and the first episode of HEADACHE (Headache). On 24-Feb-2021, the patient experienced the second episode of CHILLS (Chills) and the second episode of HEADACHE (Headache). At the time of the report, last episode of CHILLS (Chills) and the last episode of HEADACHE (Headache) outcome was unknown. Not Provided          No Concomitant medication were reported. Treatment medication includes Coricidin.
Fever, body aches, headache, swelling, fatigue, dizziness, weakness
Vision problems; This case was reported by a consumer via call center representative and described the occurrence of abnormal vision in a female patient who received Flu Seasonal QIV  (FluLaval Quadrivalent 2017-2018 season) (batch number GM2TF, expiry date unknown) for prophylaxis.   Co-suspect products included flu seasonal qiv pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received FluLaval Quadrivalent 2017-2018 season and Flulaval Tetra Pre-Filled Syringe Device. On an unknown date, unknown after receiving FluLaval Quadrivalent 2017-2018 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced abnormal vision. On an unknown date, the outcome of the abnormal vision was unknown.   It was unknown if the reporter considered the abnormal vision to be related to FluLaval Quadrivalent 2017-2018 season and Flulaval Tetra Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 2-Sep-2022 Reporter's Comment: Reporter stated that patient after receiving Flulaval QIV in 2017, had experienced vision problems, after receiving the vaccine. The caller declined to provide any information, aside from their first name and phone number.  All information provided had been reported. There was no further information or demographics available. The reporter did not consent to follow up.; Sender's Comments: Caller is the patient. Caller reported receiving Flulaval QIV in 2017. Caller reported they have experienced vision problems, after receiving the vaccine. Did not consent to follow-up. Call Notes:Caller declined to provide any information, aside from their first name and phone number. ALL INFORMATION PROVIDED HAS BEEN REPORTED. THERE IS NO FURTHER INFORMATION/DEMOGRAPHICS AVAILABLE.
No other AE and no PQC; HCP calling to report an administration of MMR II following a not supported temperature excursion.  HCP confirms no symptoms have been reported and no further details provided.  No other AE and no PQC; This spontaneous report has been received from a physician, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.  On 31-JUL-2023, the patient received measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) injection, lot #W022944, expiration date was not reported but it was stablished upon internal validation as 06-APR-2024, administered for prophylaxis (strength, and route of administration were not provided). The vaccine was administered following a not supported temperature excursion. The physician confirmed that no symptoms were reported.
After receiving the Pfizer vaccination I experienced a breakthrough of COVID and my blood pressure has not been controlled since.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     It was unknown if patient had any acute illnesses at the time of vaccination and up to one month before. It was unknown if the patient had chronic or long-standing health conditions.     On 12-Feb-2022 at 2:09 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 12-Feb-2022 at 2:09 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 12-Feb-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  It was unknown if any prescriptions, over-the-counter-medications, dietary supplements or herbal remedies were being taken by the patient at the time of vaccination and/or at the time of the adverse event. It was unknown if other vaccines were given on the same day or within one month prior to any dose of as Moderna COVID-19 Vaccine to the patient.  Vaccine administration time was given as 14:09:54.  No treatment information was provided by the reporter.   This case was linked to MOD-2022-542869 (Patient Link).
Starting on the day of the vaccine, 6 hours afterwards I had  left arm pain and notice a blister appeared. I also had upset stomach, headache, and  diarrhea.  By the next morning,  most symptoms resolved but the rash remaining and diarrhea.   The rash is raised, blister-like, measles looking, itchy and painful and now all over my body from head to toe.  I did not take any medication.  I went to see the doctor and was prescribed 2 topical creams which not help.  The rash continue to spread.  I let it run its course and now it's slowly improving.  I am still having daily diarrhea.
no adverse event; 1 dose of Moderna bivalent was given BUD; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD) and NO ADVERSE EVENT (no adverse event) in a 73-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 066H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 19-Apr-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 19-Apr-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (1 dose of Moderna bivalent was given BUD).    No concomitant medication were reported. No treatment information was provided by the reporter.
On 10/23/2022, I had blood in my urine and went to urgent care assuming it was a UTI. I was given cefalexin and they sent the urine sample off for evaluation. When I followed up with the NP, she recommended that I go see a urologist just to make sure it wasn't cancer. I went to a doctor that I haven't been to before. I went for one visit and he recommended that I get a CT scan. The CT scan showed a large mast on my kidney. He referred me to a choice of two surgeons. A family friend recommended me to the surgeon that I saw. I had surgery the Monday after the holiday and removed the kidney with the tumor. All the margins were clear, lymph nodes were clear. I was started on KEYTRUDA in February as a precautionary thing to self reduce the chance that something may occur and we're monitoring how I am with the medication. I'm waiting on the biopsy for my thyroid nodules as well. Next week I'm getting an echocardiogram and an EKG to see about some recent shortness of breath. They noted that the tumor had been on my kidney for some time because it was so big.
Shortness of breath, bilateral leg swelling, chest pain, fever 103, saturation?s in low 80s lead be to the ER and ultimately admission into the hospital. Elevated WBC, d-dimer, LFTs, CT showed bilateral lung infiltrates, ECHO showed dilated right atrium and pulmonary hypertension
injection site was red, warm and tender along with body aches and temperature of 100.2 - very sore arm
Patient reported soreness, redness and inflamed at site. MD stated to patient that it was infected and inflamed.
Wheezing noted at 30min afterward immunization in well known asthmatic pt. Px- Alisol, albuterol and PO Preloxe. Resolve excellent. Pulse ox 97
pt recv vax FEB97 & devel a rash consisting of approx 5-6 lesions around the inj site;
lightheaded; headache; muscle aches; pain at the injection site; flu like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), DIZZINESS (lightheaded), HEADACHE (headache), MYALGIA (muscle aches) and INJECTION SITE PAIN (pain at the injection site) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), HEADACHE (headache), MYALGIA (muscle aches) and INJECTION SITE PAIN (pain at the injection site). On 25-Mar-2021, the patient experienced DIZZINESS (lightheaded). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms), DIZZINESS (lightheaded), HEADACHE (headache), MYALGIA (muscle aches) and INJECTION SITE PAIN (pain at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medications were not provided
Cannot move around; Aching so bad; I feel horrible; A spontaneous report was received from a consumer concerning a 67-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events feel like have covid again, aching so bad, cannot move around and feel horrible.  The patient's medical history was not provided. Concomitant medications reported were Metformin, Lantus, Humalog for unknown indication.  On 25 Feb 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 007M20A) intramuscularly in left arm for prophylaxis of COVID-19 infection.  On 26 Feb 2021, the patient experienced the events feel like have covid again, aching so bad, cannot move around and feel horrible.  Treatment details included Aspirin.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events feel like have covid again, aching so bad, cannot move around and feel horrible was unknown.
11/6/00 immunization given, pt was playing with a piece of paper on 11/17/00 and fell hitting his left thigh on a chair. Left thigh began swelling at that time, thigh became hot and painful. Child was seen a the clinic and told there was a sterile abscess in left thigh. Mother stated there was a small knot in left thigh. Had no temp, pain or discomfort.
Tiredness; headache; joint and muscle pain; joint and muscle pain; fever; nausea; vomiting; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 18Apr2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), cyanocobalamin (B 12), colecalciferol (VIT D3), zinc (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EL3302) via an unspecified route of administration in the left arm on 21Mar2021 at 10:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 22:00, the patient experienced tiredness, headache, joint and musical pain, fever, nausea, and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness, headache, joint and musical pain, fever, nausea, and vomiting was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
I got COVID-19, I was tired for a few days. I was sneezing, had a runny nose and was tired. They lasted 2 days and were mild. I took an antiviral.
This is a spontaneous report from a non-contactable nurse via a Pfizer company representative. This nurse reported similar events for two patients. This is the first of two reports. A female patient of an unspecified age, race and ethnicity received TRUMENBA at single dose on the arm (deltoid) via an unspecified route of administration on an unspecified date for immunization. The patient medical history and concomitant medications were not reported. The patient experienced redness and swelling at the vaccination area (on the shoulder) on an unspecified date. Outcome was unknown. No follow-up attempts are possible, information about batch number cannot be obtained. Sender's Comments: Linked Report(s): US-PFIZER INC-2018100908 same reporter/product/event, different patient.
felt weak legs; felt herself miserable; still "throw up"; extremely bad shaking; real bad severe diarrhea; headache; extreme nausea; chills; little anxiety; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MUSCULAR WEAKNESS (felt weak legs), DEPRESSED MOOD (felt herself miserable), ANXIETY (little anxiety), TREMOR (extremely bad shaking) and DIARRHOEA (real bad severe diarrhea) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Hodgkin's lymphoma. Concomitant products included AMLODIPINE, HYDROCHLOROTHIAZIDE, LEVOTHYROXINE, ZOLPIDEM, ACETYLSALICYLIC ACID (ASPIRIN 81) and OMEPRAZOLE for an unknown indication.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, the patient experienced ANXIETY (little anxiety). On 25-Mar-2021, the patient experienced TREMOR (extremely bad shaking), DIARRHOEA (real bad severe diarrhea), HEADACHE (headache), NAUSEA (extreme nausea) and CHILLS (chills). On 26-Mar-2021, the patient experienced DEPRESSED MOOD (felt herself miserable) and VOMITING (still "throw up"). On 27-Mar-2021, the patient experienced MUSCULAR WEAKNESS (felt weak legs). On 25-Mar-2021, ANXIETY (little anxiety), TREMOR (extremely bad shaking), DIARRHOEA (real bad severe diarrhea), HEADACHE (headache) and CHILLS (chills) had resolved. On 26-Mar-2021, NAUSEA (extreme nausea) had resolved. At the time of the report, MUSCULAR WEAKNESS (felt weak legs), DEPRESSED MOOD (felt herself miserable) and VOMITING (still "throw up") outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included IV Hydration and IV infusion with Zofran.   Most recent FOLLOW-UP information incorporated above includes: On 12-May-2021: Follow up received on 12-May-2021 and patient medical history was added.
Right upper arm, neck and arm pit hurt. A few days later she noticed swelling in the armpit that became progressively worse. She also had numbness and tingling in her right arm and hand.
About 3 PM she received her second vaccination for Covid.  She states that she has a history of adverse reactions to flu vaccines that are anaphylactic like in the past.  She usually premedicates with Benadryl and steroids.  Today she did take 100 mg of Benadryl prior to her vaccination.  Shortly after receiving the vaccine, she did feel like her throat was getting a little bit tight but she did not feel like it was true anaphylaxis.  However she then felt very off.  After this vaccine her throat started to feel tight, and she stated she did not feel well overall.  She did have some tunnel vision and was shaky. At about 1730 her heart rate drops to the 30s, she started feeling itchy, and then she went into a coughing fit and started to feel her throat close. She received 0.3 mg IM epinephrine, 20 mg IV famotidine, 125 mg IV methylprednisone, 0.5 mL of nebulized racepinephrine, and 500 mL NS bolus. She has since recovered and is stable on room air.